CompletedPhase 4

Interstitial Cystitis: Examination of the Central Autonomic Network

United States72 participantsStarted 2017-03-01

Plain-language summary

This proposal aims to move the science of chronic pelvic pain (CPP) from simple associations towards an investigation of cause and effect relationships. The investigators will determine whether the striking changes in autonomic nervous system responsiveness (ANS-R) contribute meaningfully to the pathogenesis of CPP.

Who can participate

Age range18 Years – 80 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Pelvic injection
✕. Pelvic floor therapy
✕. Agents with specific FDA approval for IC/BPS or MPP (e.g., Elmiron)
✕. Anticonvulsants
✕. Tricyclic agents
✕. Intravesical therapy or Botox
✕. Bladder hydrodistention

What they're measuring

Total Score on Genitourinary Pain Index (GUPI) Scale

Timeframe: Weeks 4, 12 and 24

Average Score on the First Domain of the Multidimensional Pain Scoring (MPI) Scale

Timeframe: Weeks 4, 12 and 24

Trial details

NCT IDNCT03008382

SponsorVirginia Commonwealth University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03-16

Results submitted2024-10-08

View on ClinicalTrials.gov More Interstitial Cystitis/Painful Bladder Syndrome trials